retatrutide triple agonist phase 2 nejm 2023 obesity results Retatrutide: A Shaping the Future of Metabolic Care Original Article: Triple–Hormone-Receptor Agonist Retatrutide

Journal of Neurochemistry, 97(2), 303309

FIGURE 2 The random-effects relative treatment estimates versus metformin are shown in Figure 2B, followed by exploratory SUCRA and rank-probability summaries in Figures 2C,D and posterior density/ROPE summaries in Figure 2E

JAMA Surg 158(10):10031011 Miras AD et al (2019) Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

Get complete access to select stories, free newsletters and podcasts

This can alter alcohols addictive potential as the pharmacokinetics of a substance is known to influence intake 44,45,46,47,48,49,50